Chapter

Neurobiology of Respiration

Volume 788 of the series Advances in Experimental Medicine and Biology pp 19-23

Date:

Siglec-8 in Induced Sputum of COPD Patients

  • R. M. MrozAffiliated withDepartment of Chest Diseases and Tuberculosis, Bialystok Medical University Email author 
  • , A. HolowniaAffiliated withDepartment of Clinical Pharmacology, Bialystok Medical University
  • , P. WielgatAffiliated withDepartment of Clinical Pharmacology, Bialystok Medical University
  • , A. SitkoAffiliated withDepartment of Clinical Pharmacology, Bialystok Medical University
  • , T. SkopinskiAffiliated withDepartment of Clinical Pharmacology, Bialystok Medical University
  • , E. ChyczewskaAffiliated withDepartment of Chest Diseases and Tuberculosis, Bialystok Medical University
  • , J. J. BraszkoAffiliated withDepartment of Clinical Pharmacology, Bialystok Medical University

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Chronic obstructive pulmonary disease (COPD) is related to infiltration and activation of inflammatory cells in airways and pulmonary tissue. In COPD, neutrophils are prominent, while eosinophilic influx is typical to asthma. Inflammatory cells express sialic acid-binding immunoglobulin like lectins called Siglecs, a family of innate immune receptors that are transmembrane I-type lectins binding sialic acid. One member of the Siglec family, Siglec-8, is expressed mostly in eosinophils and may be an important therapeutic target in asthma or COPD. The aim of our project was to quantify Siglec-8 expression in induced sputum cells of COPD patients treated with long-acting beta2-agonists (LABA) or combined with long-acting antimuscarinic agents (LAMA) – tiotropium bromide. Thirty stable COPD patients (21 males and 9 females, mean age 67 years) receiving 12 μg BID formoterol therapy were assessed before and after 3 months’ add-on therapy consisting of 18 μg QID tiotropium. In all patients, spirometry, lung volumes, and DLCO were performed before and after therapy. The patients were subjected to sputum induction before and after therapy. Sputum cells were isolated and processed to obtain cell membranes. Siglec-8 protein expression was assessed using Western blot. In patients receiving tiotropium and formoterol, improved FEV1 and lung volumes were observed compared with formoterol-only treated patients. The mean Siglec-8 level was significantly higher in eosinophilic subgroup of COPD patients compared with non-eosinophilic patients before therapy 40,000 vs. 15,000 Adj. Vol. INT/mm2. Our data show that Siglec-8 may be involved in COPD pathogenesis and may influence COPD phenotyping.

Keywords

COPD Siglec-8 Sputum induction Tiotropium Treatment